Hapten Synthesis and Monoclonal Antibody Preparation for Simultaneous Detection of Albendazole and Its Metabolites in Animal-Origin Food

Shibei Shao, Xuping Zhou, Leina Dou, Yuchen Bai, Jiafei Mi, Wenbo Yu, Suxia Zhang, Zhanhui Wang and Kai Wen *

Abstract: Albendazole (ABZ) is one of the benzimidazole anthelmintics, and the overuse of ABZ in breeding industry can lead to drug resistance and a variety of toxic effects in humans. Since the residue markers of ABZ are the sum of ABZ and three metabolites (collectively referred to as ABZs), albendazole-sulfoxide (ABZSO), albendazole-sulfone (ABZSO₂), and albendazole-2-amino-sulfone (ABZNH₂SO₂), an antibody able to simultaneously recognize ABZs with high affinity is in urgent need to develop immunoassay for screening purpose. In this work, an unreported hapten, 5-(propylthio)-1H-benzo[d]imidazol-2-amine, was designed and synthesized, which maximally exposed the characteristic sulfanyl group of ABZ to the animal immune system to induce expected antibody. One monoclonal antibody (Mab) that can simultaneously detect ABZs was obtained with IC₅₀ values of 0.20, 0.26, 0.77, and 10.5 µg/L for ABZ, ABZSO₂, ABZSO, and ABZNH₂SO₂ in ic-ELISA under optimized conditions respectively, which has been never achieved in previous reports. For insight into the recognition profiles of the Mab, we used computational chemistry method to parameterize cross-reactive molecules in aspects of conformation, electrostatic fields, and hydrophobicity, revealing that the hydrophobicity and conformation of characteristic group of molecules might be the key factors that together influence antibody recognition with analytes. Furthermore, the practicability of the developed ic-ELISA was verified by detecting ABZs in spiked milk, beef, and liver samples with recoveries of 60% to 108.8% and coefficient of variation (CV) of 1.0% to 15.9%.

Keywords: albendazole; metabolites; hapten design; antibody; immunoassay; computational chemistry

1. Introduction

Albendazole (ABZ, shown in Figure 1a), one of benzimidazoles, is an effective anthelmintic and often used to control soil-transmitted helminth infection in humans and animals. ABZ is usually the first choice for treatment of parasitic diseases, such as cystic echinococcosis and alveolar echinococcosis [1–3], and for eliminating lymphatic filariasis in endemic areas [4–6]. After administration of ABZ, the kinds of residues that can be monitored depend on the route of administration, target tissue or the detection time after treatment. At early periods, the most likely residues are albendazole sulfoxide (ABZSO) and albendazole sulfone (ABZSO₂), while albendazole 2-amino sulfone (ABZNH₂SO₂) may be the most persistent residue in tissue at longer withdrawal periods [7,8]. Residues of ABZ in animal food can lead to embryonic toxicity for consumer, as well as teratogenic and mutagenic effects [9,10]. The European Union (EU) has set the maximum residue limits (MRLs) for ABZs (sum of ABZ, ABZSO, ABZSO₂, and ABZNH₂SO₂, Figure 1a) at...
100 µg/kg (L) in milk/muscle/fat, 500 µg/kg in kidney, and 1000 µg/kg in liver [11]. The U.S. FDA has set different residue limits in different samples, for example, 200 µg/kg in liver, 50 µg/kg in muscle [12]. The Ministry of Agriculture and Rural Affairs of China has set the MRLs (GB 31650-2019) for ABZs (sum of ABZ, ABZSO, ABZSO₂, and ABZNH₂SO₂) at 100 µg/L in milk, and for ABZNH₂SO₂ at 100–5000 µg/kg in edible tissues of food-producing species [13]. To ensure food safety, various instrumental methods have been established for determining ABZs in animal-derived food [14–19]. Although these methods are highly sensitive, they rely heavily on expensive instruments and skilled personnel, which often cannot meet the current urgent need for fast screening. Thus, there is great interest in the development of accurate and fast methods.

Figure 1. Chemical structures and synthesis route used in the study: (a) Chemical structure of four ABZs. (b) Synthesis route of hapten and immunogen. (c) Mass spectrometry characterization of hapten and (d) Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry characterization of hapten- bovine serum albumin (BSA) conjugates.

Immunoassays, based on antibody-antigen recognition, offer a convenient and rapid alternative to instrumental methods and are currently the most widely used screening methods in food safety. Though immunoassay has many advantages including high-throughput, rapidity, and on-line detection, few studies have been conducted on immunoassay devel-
development due to the unavailability of antibody with high affinity and specificity to all ABZs, especially ABZNH₂SO₂. There have been only several reports of antibodies production for benzimidazoles including some of ABZs (Table 1), but all of the antibodies were of limited affinity to ABZNH₂SO₂, and the non-specificity binding to various benzimidazoles greatly constrained its application in detection of ABZs. Hapten design is the key to producing antibody with desired affinity and specificity. In previous studies, the strategy of maintaining the common moiety of benzimidazoles, carbamate group as the epitope [20–23] was used to obtain a broad-spectrum antibody. To the best of our knowledge, no report describing the production of antibody able to sensitively and specifically recognize all four ABZs has been reported despite of the great demand. In the present study, we described the synthesis of one new hapten, production of a Mab with highly specificity, exploration of antibody recognition mechanism, and development of an indirect competitive ELISA (ic-ELISA) for the determination of ABZ and its metabolites in milk and tissue simultaneously with improved sensitivity.

Table 1. Specificities of reported antibodies against ABZs in the literatures.

| Compounds       | Haptens&IC₅₀ (μg/L) | [22] | [21] | [20] | This study |
|-----------------|---------------------|------|------|------|------------|
|                 |                     |      |      |      |            |
| ABZ             | 1.4                 | >10,000 | 0.66 | 0.2  |            |
| ABZSO₂          | 1.8                 | 1253.2 | 5.34 | 0.26 |            |
| ABZSO           | 1.5                 | 2241.4 | 2.91 | 0.77 |            |
| ABZNH₂SO₂       | >10,000             | 85.2  | >1000 | 10.5 |            |
| Carbendazim     | - ¹                 | -     | 14.84 | >312.5 |          |
| Fenbendazole    | 3.8                 | >10,000 | 0.75 | 1.68 |            |
| Fenbendazole sultone | 8.3                 | -     | 6.27 | -    |            |
| Flubendazole    | 0.63                | >10,000 | 0.37 | 3.68 |            |
| Mebendazole     | 2.4                 | >10,000 | 0.64 | 4.14 |            |
| Oxibendazole    | 0.62                | >10,000 | 19.99 | >312.5 |          |
| Oxibendazole    | 1.4                 | >10,000 | 1.13 | -    |            |
| Parbendazole    | -                   | -     | -    | -    |            |
| Cambendazole    | >100                | -     | >1000 | -    |            |
| Thiabendazole   | >100                | >10,000 | -    | >312.5 |          |

¹ Not mentioned or not detected.

2. Materials and Methods
2.1. Reagents and Materials

ABZ, ABZSO₂, ABZSO₂, fenbendazole, flubendazole, mebendazole, oxibendazole, oxendazole, triclabendazole, carbendazim, and thiabendazole were purchased from J&K Chemical Technology (Beijing, China). Carboxydiimidazole and other chemical reagents were supplied by Sinopharm Chemical Reagent (Beijing, China). Ovalbumin (OVA), bovine serum albumin (BSA), hypoxanthine aminopterin thymidine (HAT), complete and incomplete Freund’s adjuvant, poly (ethylene glycol) (PEG) 1500, and fetal bovine serum were acquired from Sigma–Aldrich (St. Louis, MO, USA). Goat anti-mouse IgG (HRP labeled) was purchased from Jackson Immuno Research (West Grove, PA, USA). Cell culture medium (DMEM) was supplied by Thermo Fisher Scientific (Waltham, MA, USA). Distilled water used in this study was obtained from a Milli-Q purification system (Bedford, MA, USA). Microplates for ELISA were acquired from Costar (Cambridge, MA, USA). Flat-bottomed high-binding polystyrene cell culture plates were obtained from Corning Life Sciences (New York, NY, USA). Balb/c mice were supplied by Beijing Vital River Laboratory Animal Technology.
2.2. Preparation of hapten and conjugates

2.2.1. Synthesis and Identification of Hapten

The hapten synthesis route is shown in Figure 1b and briefly described as follows: 500 mg of ABZ was firstly dissolved in 5.0 mL of ethanol in a round bottom flask with a magnetic stirrer, and then 10 mL of hydrochloric acid was added and heated to 80 °C for 30 min with stirring and monitored by thin-layer chromatography. After reaction, the pH value of the mixture was adjusted to 9.0 by using 2 M of sodium hydroxide solution, and extracted twice with 30 mL of ethyl acetate. The organic phase was combined and dried by using 2.0 g water-free sodium sulfate and the precipitate were removed. Then, 1.5 g of 100–200 mesh silicon was added to the organic phase and then dried for subsequent column chromatography (40 g 200–300 mesh chromatography silicone, eluted by petroleum ether: ethyl acetate 4:1). Finally, the hapten was obtained and vacuum-dried for mass spectrometry confirmation as shown in Figure 1c.

2.2.2. Synthesis and Identification of Immunogen and Coating Antigen

Amino groups of the acquired hapten were conjugated to carrier proteins by using carbonyldiimidazole as coupling reagent. Firstly, 9.2 mg of hapten was dissolved in 1.5 mL of DMF and stirred at 200 rpm for 10 min, then 7.6 mg carbonyldiimidazole was added, and the solution was stirred at room temperature (500 rpm) for 3 h to obtain activated hapten for subsequent coupling with carrier protein. Next, 50 mg of BSA was dissolved in 3.5 mL of 0.1 M of sodium bicarbonate solution, stirred at 200 rpm for 10 min, then cooled down via ice-bath. The previous activated hapten was then dropped into the protein solution at a rate of 1.0 mL/min under 1000 rpm stirring, then mixed at 500 rpm for 24 h. The reaction products were dialyzed for 3 days against phosphate buffer solution (PBS, 0.01 M, pH 7.2) under 4 °C. Finally, the product was centrifuged at 5000 rpm for 6 min to harvest the purified supernatant and stored at −20 °C until use. Immunogen was characterized by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS, see Figure 1c) and the conjugation ratio was calculated as follows:

\[
\text{Conjugation ratio} = \frac{M (\text{conjugates}) - M (\text{BSA})}{M (\text{haptns})} 
\]

Coating antigen was synthesized using the above-mentioned procedure, except OVA was substituted for BSA.

2.3. Production of Monoclonal Antibody

All animal experiments were conducted in strict accordance with Chinese laws and guidelines approved by the animal ethics committee of China agricultural university. Eight Balb/c female mice aged 8 weeks were immunized with immunogen (diluted in PBS to 1.0 mg/mL) at a dose of 100 μg per mouse on an identical schedule. For primary immunization, mice were injected subcutaneously with a fully emulsified mixture of equal volumes complete Freund’s adjuvant and prepared immunogen. For enhancement, mice were immunized with an emulsified mixture of immunogen and incomplete Freund’s adjuvant every 3 weeks. A total of 4 immunizations were administered with the last one given via intraperitoneal injection without the adjuvant. To better monitor the serum titer and specificity by ic-ELISA, serum was collected 7–14 days after each immunization, according to results of a dynamics study of the antibody-mediated immune response [24]. Four days after the last boost immunization, mice spleen cells were separated and fused with PEG 1500 pre-treated sp2/0 myeloma cells to prepare hybridomas according to procedures described previously [25–27]. The fused cells were cultured in HAT medium for 7 days and were screened by testing the supernatant using ic-ELISA to determine the binding ability. The positive and highly sensitive hybridomas were obtained after subcloning four times using the limiting dilution method. Finally, the hybridomas were
Foods 2021, 10, 3106

intraperitoneally injected into mice, and the ascites collected from mice were extracted and purified with saturated ammonium sulfate to obtain purified Mabs.

2.4. Development and Optimization of ic-ELISA

An ic-ELISA was established under the following optimized assay conditions: microplates were coated with 100 µL of coating antigen dissolved in 0.05 M carbonate buffer and incubated at 37 °C for 2 h. The plates were then washed three times for subsequent blocking. A volume of 150 µL/well of blocking buffer was added and incubated at 37 °C for 1.5 h, after which the buffer was removed. For the competitive step, both 50 µL of competitor and 50 µL of antibody working solution were pipetted into each well and incubated at 37 °C for 30 min. The plates were then washed three times, 100 µL/well of goat-anti-mouse IgG-HRP diluted in PBS (1:5000) was added, and the plates were incubated at 37 °C for 30 min. The plates were washed as above, 100 µL/well of newly prepared substrate solution was added, and the plates were incubated at 37 °C for 15 min. Finally, the chromogenic reaction was terminated with 50 µL/well H₂SO₄ (2 M). Optical density (OD) values at 450 nm were measured with a Multiskan FC machine by Thermo Scientific (Shanghai, China). The OD₄₅₀ values were plotted against the analyte concentration on a logarithmic scale, and the generated sigmoidal curve was mathematically fitted to a four-parameter logistic equation using the OriginPro 8.5 software (OriginLab Corporation, Northampton, MA, USA).

\[
Y = \frac{(A - D)}{(1 + (X/C)^B)} + D
\]  

(2)

where A = response at high asymptote, B = the slope factor, C = concentration corresponding to 50% specific binding (IC₅₀), D = response at low asymptote, and X = the calibration concentration.

Several physicochemical factors were optimized to improve the performance of ic-ELISA, including pH and ionic strength of working solution.

2.4.1. Effect of pH

The effect of varying the pH on the ic-ELISA was tested by dissolving the analytes and Mabs in PBS buffer at a specified pH and adding them to the antigen coated plates in equal volumes (50 µL/well). The pH values of 5.5, 6.5, 7.0, 7.4, and 8.5 were tested in the ic-ELISA incubation step with all other parameters of the assay fixed.

2.4.2. Effect of Ionic Strength

The effect of ionic strength of assay buffer on the ic-ELISA performance was studied using different NaCl concentrations of 0.05, 0.1, 0.15, 0.2, 0.4, and 0.8 M in 0.01 M of phosphate buffer, respectively. The effects of these salt concentrations were evaluated on the ic-ELISA by comparing the ABZ competition curves measured with each buffer at pH 7.4.

2.5. Cross-Reactivities and Computational Chemistry Analysis

The specificity of the developed ELISA was assessed using cross-reactivity (CR) determined under optimal conditions. The CRs of ABZs and other widely used benzimidazole anthelmintics, such as fenbendazole, oxibendazole, mebendazole, flubendazole, oxendazole, triclabendazole, carbendazim, and thiabendazole, were calculated according to the following equation:

\[
CR = \frac{IC_{50} \text{ (ABZ, } \mu g/L)}{IC_{50} \text{ (analytes, } \mu g/L)} \times 100\% 
\]  

(3)

The computational chemistry method, which can provide electrostatic potential and conformational information of the molecule regarding antibody recognition, was employed here to study the CRs of immunoassays and the binding interactions between small molecules and antibody. All 3D structures were built in Gaussian 09 (Gaussian Inc., Wallingford, CT, USA) and then optimized by the density functional theory calculations
with the M06-2X density functional and TZVP basis set. Basing on the lowest energy conformations, molecular alignments were materialized by molecular overlay modules in Discovery Studio 2019 (Accelrys Software, Inc., San Diego, CA, USA). The degree of molecular superposition was measured by alignment root-mean-square-deviation (RMSD). The quantitative molecular surface analysis in the Multiwfn software package was then applied together with VMD to analyze molecular electrostatic potential (ESP) and map ESP on van der Waals surface [28,29]. The molecule volume, and total polar surface area (TPSA) were extracted using the Multiwfn 3.7(develop) code. Dipole moment (µ) was extracted from the Gaussian output file. The Log P was obtained using ChemDraw (PerkinElmer, Waltham, MA, USA). By analyzing steric and electrostatic contour maps of the region around the molecule with respect to changes in affinity, the structure–activity relationship between the drugs and the Mab was studied.

2.6. Sample Preparation

Negative samples (milk, muscle, and liver of bovine) were obtained from the National Reference Laboratory for Veterinary Drug Residues (Beijing, China). Tissue samples (muscle and liver) were spiked with ABZNH₂SO₂, and milk was spiked with ABZ/ABZSO/ABZSO₂/ABZNH₂SO₂. Three grams (milliliters) homogenized sample were weighed into a 50-mL centrifuge tube with 1.0 g of sodium sulfate for pretreatment. Two milliliters of 50% NaOH (only tissue sample) and 9.0 mL of ethyl acetate were then added to the above tube. The mixture was vortexed for 5 min and centrifuged at 4000 rpm for 10 min. Next, 4.5 mL of the supernatant was transferred into a new tube and dried at 60 °C under a nitrogen stream. One milliliter of n-hexane and 0.5 mL of acetonitrile were added to the dried tube for cleaning and resuspension and followed by centrifugation at 4000 rpm. The upper n-hexane and commixture was discarded then, and 0.1 mL of the remaining liquid was pipetted into a new centrifuge tube and mixed with 0.9 mL PBS (0.01 M) (for milk samples) or 1.9 mL PBS (for tissue samples) for detection. The limit of detection (LOD) was determined as the 10% inhibition concentration (IC₁₀) calculated from calibration curves. All measurements were completed in triplicate.

3. Results and Discussion

3.1. Hapten Design and Characterization

Hapten structure determines the specificity and affinity of the resulting antibody [30]. To produce the antibody that could recognize ABZs, the characteristic structure of these compounds should be maximumly exposed to immune system. Previous studies have designed hapten by maintaining the carbamate group, which is a common structure in major benzimidazoles, to prepare antibodies with broad-spectrum specificities [20]. Some of the obtained antibodies could detect ABZ with affinity of 0.66 to 1.4 µg/L (Table 1), but showed poor affinity to ABZ metabolites especially ABZNH₂SO₂, which are critical residue markers of ABZ. Even worse, the specificities of these antibodies were insufficient because of the recognition of many other benzimidazoles with CRs of 3% to 88%. A similar result was also observed in another study, in which the ABZNH₂SO₂ was directly used as hapten to produce antibodies against ABZNH₂SO₂ [21].

In this study, we designed a new hapten of ABZs as shown in Figure 1b and Table 1. The feature structure of ABZ, the sulfanyl group, was maximumly exposed to immune system to induce an antibody with specific recognition of ABZs by conjugating with proteins at the carbamate moiety. Besides the increasing in complexity of epitope (often means stronger antigenicity) relative to previous ones, another key point in this design is that the retained sulfanyl group of ABZ could better maintain the characteristic structures of ABZs, which are structurally different from other benzimidazoles. The hapten was identified by High performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS, as shown in Figure 1c) (Agilent Technologies, Santa Clara, CA, USA) and ¹H nuclear magnetic resonance spectrometry (NMR, see Figure S1 in Supplementary Materials) (Bruker, Rheinstetten, Germany), and the molecular ions (m/z) of hapten were 207.98,
indicating that the hapten was successfully obtained. The hapten-BSA conjugate was then used as the immunogen, while hapten-OVA as the coating antigen. The immunogen was characterized by MALDI-TOF-MS (Bruker, Rheinstetten, Germany). The correct molecular weight of the hapten molecular ion and conjugate were observed (see Figure 1d), demonstrating that the hapten had been conjugated to the carrier protein, and the calculated conjugation ratio of hapten to BSA was 8.8:1.

3.2. Development and Optimization of the ic-ELISA

Four ABZs, including ABZ, ABZSO₂, ABZSO, and ABZNH₂SO₂, were used to determine the affinity (expressed by IC₅₀) and specificity (expressed by CR) of antibodies using homologous coating antigen. The results indicated that the obtained antibodies 12F12, 12H3, and 4E1 could recognize ABZs with varied affinities (IC₅₀ values of antiserum were from 0.12 µg/L to beyond 100 µg/L). As shown in Figure 2a, the antibody 4E1 exhibited relatively higher affinity to ABZ and ABZSO, but relatively worse recognition towards ABZNH₂SO₂; 12H3 had high affinity to three ABZs but unfavorable affinity to ABZNH₂SO₂; while the antibody 12F12 showed high affinity to all four ABZs and was selected for further optimization.

Figure 2. Optimization of ic-ELISA. The IC₅₀ was calculated when the Amax (Optical density (OD) value of negative control) ranged from 1.0 to 2.0. (a) Screening of Mab. Each Mab was estimated using four ABZs separately. The effect of (b) pH value and (c) ionic strength in the ic-ELISA were evaluated using Mab 12F12 and ABZ. (d) Standard curves of ic-ELISA for ABZs. (e–j) the calibration curves of the ic-ELISA for (e) ABZ, (f) ABZSO₂, (g) ABZSO, (h) ABZNH₂SO₂ in phosphate buffer solution (PBS) and milk, and of ABZNH₂SO₂ in extracted (i) bovine liver and (j) beef. Each value represents the average of three independent replicates.
The development and optimization procedure were performed according to previous studies [25,26]. Ionic strength and pH value of working buffer were further optimized. The $A_{\text{max}}$ (means the OD value of negative control)/IC$_{50}$ ratio was introduced here to be a criterion for optimization, and a higher ratio value meant a higher sensitivity. It can be seen that the ratio of $A_{\text{max}}$/IC$_{50}$ was highest at an ionic strength of 0.15 mol/L (Figure 2b) and pH 7.4 (Figure 2c). Thus, the optimum conditions (pH 7.4 and 0.15 mol/L NaCl in PB buffer, namely, 0.01 M PBS) were used in subsequent experiments.

The sensitivity of the ic-ELISA was characterized by IC$_{50}$ values from standard curves under the optimized conditions. Standard curves of ABZ/ABZSO$_2$/ABZSO were established at 27.0, 9.0, 3.0, 1.0, 0.33, 0.11, 0.037, 0.012, 0.004, 0.001, and 0 µg/L in PBS, standard curves of ABZNH$_2$SO$_2$ were established at 270, 90, 30, 10, 3.33, 1.11, 0.37, 0.12, 0.04, 0.01, and 0 µg/L in PBS. As shown in Figure 2d, the developed ic-ELISA based on antibody 12F12 could detect ABZ, ABZSO$_2$, and ABZSO with IC$_{50}$ values below 1.0 µg/L (0.20, 0.26, and 0.77 µg/L), and ABZNH$_2$SO$_2$ with IC$_{50}$ values of 10.5 µg/L in PBS buffer, which is of the highest affinity so far. The results shown that the sensitivities of the developed ic-ELISA were times better than those of other reported immunoassays for ABZs (Table 1).

### 3.3. Cross-Reactivities and Structure-Activity Relationship Study by Computational Chemistry

In the process of antibody-antigen recognition, cross-reactivity would arise if the configuration of the antigen matches the active pocket of the antibody [31,32]. As shown in Table 2, the ic-ELISA exhibited varied CRs with ABZ (100%), ABZSO$_2$ (76.9%), ABZSO (26.0%), ABZNH$_2$SO$_2$ (1.9%), and other often-used benzimidazoles (fenbendazole, flubendazole, mebendazole, oxibendazole) less than 8%. The relative lower CR value of ABZNH$_2$SO$_2$ (CR = 1.9%) can easily draw our attention, which shares similar structure with ABZSO$_2$ (CR = 76.9%), except for the carbamate group on the right of molecule in the case of ABZSO$_2$. As the sulfanyl group of hapten was exposed to immune system as a characteristic epitope in primary hapten design, it would be the site for the antibody recognition. While the remote amide group, which formed after the hapten was coupled to carrier protein, should be masked by carrier protein and contribute much less for antibody recognition. However, the recognition ability of the obtained Mab seemed not in accordance with expectation by analyzing only 2D dimension due to the relative poorer recognition of ABZNH$_2$SO$_2$ without a methoxyamide or carbamate group. Nevertheless, the benzimidazoles having complex (from a 2D view) side chain groups or phenyl groups (fenbendazole, flubendazole, mebendazole, oxibendazole, Table 2) surprisingly showed higher CRs than ABZNH$_2$SO$_2$. Though the ic-ELISA was with high sensitivity for detection of all ABZs and far better than previous study, it was appealing to further study on the CR data, and there was considerable interest in understanding at 3D level as well as quantitative analysis. Therefore, computational chemistry analysis was used to provide 3D conformations and quantitative information, such as configuration, electrostatic potential, and hydrophobicity of molecules, to investigate the binding of antibody to compounds. Based on their optimized lowest energy conformations of ABZs and other benzimidazoles that showed cross-reactivities, all molecules were aligned while ABZ was selected as the template. All hydrogen atoms were hidden in the optimized geometric structures for a concise view.

The hapten design of this work was based on the conjecture that the sulfanyl/sulfonyl moiety is the characteristic moiety of ABZs, thus should be retained to prepare ABZs antibodies. Figure 3a shows that when this moiety of the structure is changed, such as S atom (ABZ, in green) becomes O atom (oxibendazole, in yellow), chain alkyl group (ABZ, in green) becomes phenyl group (fenbendazole, in light blue), or both (flubendazole in brick-red, or mebendazole in grey), etc., at least a 10-fold decrease in CRs was observed, indicating the criticality of the sulfanyl/sulfonyl group of the structure. It can be seen in Figure 3a that all molecules are well coincided with ABZ, and the RMSD values of the alignments are from $2.3 \times 10^{-3}$ of ABZNH$_2$SO$_2$ to $1.3 \times 10^{-2}$ of ABZSO$_2$ and fenbendazole (Table 3), demonstrating the extent of the difference of other molecules with ABZ, which
agreed with CR data on the whole. It can also be seen in Figure 3a, the substitution of carbon or oxygen atom for sulfur atom in flubendazole (in red), mebendazole (in gray), or oxibendazole (in gray) causes changes in torsion angle of the left group towards the benzimidazole ring comparing with that of ABZ (in red), which might be partly responsible for the 10-fold decrease of Mab recognition. The ABZSO (in blue), ABZSO2 (in purple), and ABZNH2SO2 (in orange) show almost the same angle, but the difference between CRs is up to dozens of times. There shall be other factors which influence the recognition of antibody besides the contribution of molecular conformation.

Table 2. Experimental IC50 values and cross-reactivities of ABZs in optimized ic-ELISA.

| Analytes               | IC50 (μg/L) | CR (%) |
|------------------------|------------|--------|
| ABZ                    | 0.20       | 100    |
| ABZSO2                 | 0.26       | 76.9   |
| ABZSO                  | 0.77       | 26.0   |
| ABZNH2SO2              | 10.50      | 1.9    |
| Fenbendazole           | 1.68       | 11.9   |
| Flubendazole           | 3.68       | 5.4    |
| Mebendazole            | 4.14       | 4.8    |
| Oxibendazole           | 2.29       | 8.7    |
| Oxfendazole            | >312.5     | <0.01  |
| Triclabendazole        | >312.5     | <0.01  |
| Carbendazim            | >312.5     | <0.01  |
| Thiabendazole          | >312.5     | <0.01  |
Figure 3. (a) The alignment of cross-reactive analytes with ABZ based on lowest energy conformation with all of the hydrogen atoms hidden. (b) Electrostatic potential energy of analytes. The negative potential areas are indicated in blue; red coloring indicates positive potential areas, and white indicates relatively neutral areas. The blue and golden globules on the surface represent the minima and maxima of ESP (kcal/mol) on the van der Waals surface. (c) The calculated surface area distribution in different ESP ranges on the van der Waals surface.

Table 3. Comparison of cross-reactivities and molecular descriptors of benzimidazoles.

| Items            | ABZ  | ABZSO₂ | ABZSO | ABZNH₂SO₂ | Fenbendazole | Flubendazole | Mebendazole | Oxibendazole |
|------------------|------|--------|-------|-----------|--------------|--------------|-------------|--------------|
| CR (%)           | 100  | 76.9   | 26.0  | 11.9      | 5.4          | 4.8          | 8.7         |              |
| MW (g/mol)       | 265.1| 297.3  | 281.3 | 299.3     | 313.3        | 295.3        | 249.3       | 225.0        |
| volume(Å³)       | 320.9| 336.4  | 328.5 | 201.8     | 255.3        | 261.1        | 256.2       | 225.0        |
| Log P            | 2.8  | 1.2    | 1.2   | 1.0       | 3.4          | 3.1          | 2.9         | 2.4          |
| µ                | 4.1  | 7.6    | 4.7   | 6.5       | 4.8          | 6.6          | 6.8         | 1.8          |
| TPSA (Å²)        | 67.0 | 101.2  | 84.1  | 88.9      | 67.0         | 84.1         | 84.1        | 76.2         |
| alignment RMSD   | 0    | 1.3 × 10⁻² | 1.1 × 10⁻² | 2.3 × 10⁻³ | 1.3 × 10⁻² | 8.5 × 10⁻³ | 8.4 × 10⁻³ | 5.4 × 10⁻³ |

ESP describes the potential energy of a proton placed at a point near the molecule. As different substituents may affect the electrostatic field, ESP analysis helps to visualize spatial regions of molecules and to analyze electrostatic interaction between antibody and antigen [30,33]. The ESP calculations displayed on van der Waals surfaces of global lowest energy conformation are shown in Figure 3b, positive potential energy is represented by red areas around the molecules, of which the maxima were marked as golden globule, and these areas are repulsive to a proton, negative potential energy is represented by blue areas on the molecules with the minima marked as light blue globule, and these areas are attractive to a proton. It can be seen that the presence of the oxygen atom causes more negative potential surface. With consideration of almost identical structure of ABZNH₂SO₂ (CR = 1.9%) and ABZSO₂ (CR = 76.9%), except for the methoxyamide group on the right of molecule in the case of ABZSO₂ and amino group in the case of ABZSO₂NH₂, less positive potential surface can be noticed in ABZNH₂SO₂, and the reduction of electronic effect associated with the lack of group might influence the recognition by Mab. It is clearly seen from Figure 3c that the ESP surface area distribution of molecules in different ESP ranges are similar on the whole but obviously varied locally. Cross-reactive analytes seem to have
stronger electronic effect (positive or negative area) than ABZ, but do not generate better CRs. The results imply that the electrostatic potential energy might play a limited role in the antibody recognition or has been masked by other powerful factors.

Critical molecular descriptors were finally compared as shown in Table 3. Studies have shown that molecular parameters such as lipid-water partition coefficient ($\text{Log } P$, a widely used measure of hydrophobicity), dipole moments ($\mu$, represents the polarity of molecule, the larger the polarity, the stronger the hydrophilicity), and topological polar surface area (TPSA) of analytes are important factors affecting recognition by antibodies [34–36], and hydrophobic force was believed to be the main driving force between small molecules and antibody [30,34]. In this study, $\text{Log } P$ was found to be positively correlated with antibody affinity. The hydrophobicity decreases when the sulfur group in the molecule is replaced with a sulfone or a sulfoxide groups, resulting in a decrease in CR. Compared with ABZ, the hydrophobicity of ABZNH$_2$SO$_2$ greatly decreases, which is the lowest among all the analytes as well as the CR. Other compounds with strong hydrophobic groups do not show high CRs, which may be due to the co-working conformational factors. Some other physicochemical parameters that may influence the immunogenicity of haptens, including MW, SAs, and several hydrophobic parameters has also been calculated and summarized in Table 3, which shows no significant relationship with the recognition.

In general, hydrophobicity still dominates in the process of recognition in this study, and conformational factors play a partial role. Changes in the part of what we maintained as epitope in hapten design, the sulfanyl group, cause decrease in antibody recognition. This confirms the correctness of the hapten design strategy in this study, that is, the characteristic moiety of the target molecule should be maximally exposed.

### 3.4. Matrix Effect and Recovery in Samples

Milk, muscle, and liver samples from bovine were chosen to determine matrix effect and recovery. Direct dilution following sample extraction was used as a simple way to eliminate matrix effects for rapid screening purpose. The milk extracts were diluted 5/10/20 times with PBS and the tissue samples extracts were diluted 10/20/40 times with PBS. The standard curves of ABZs prepared in diluted samples were then compared with those in PBS to evaluate the matrix effects (Figure 2e–j).

Considering both $A_{\text{max}}$ and $IC_{50}$ performance, 10-fold dilution of milk samples and 20-fold dilution of tissue samples (beef and liver) in PBS were chosen to establish the calibration curves. The calculated LODs of ABZ, ABZSO$_2$, ABZSO, and ABZNH$_2$SO$_2$ were at 0.05, 0.05, 0.05, and 0.49 µg/L in milk samples, respectively, and the LODs of ABZNH$_2$SO$_2$ in beef and bovine liver samples were 1.12 and 0.56 µg/kg, which were below the MRL of ABZs. Negative foodstuffs were spiked with ABZs at concentrations of 0.5/2.0/10.0 or 10/30/90 µg/kg (L), and the average absorbance values were interpolated with calibration curves to determine recoveries. The linearity ranges (from $IC_{20}$ to $IC_{80}$), recoveries, and CVs of ABZs in spiked milk samples are shown in Table 4, and that of ABZNH$_2$SO$_2$ in spiked tissue samples are shown in Table 5. As shown in Tables 4 and 5, the recoveries ranged from 60% to 108.8%, with CVs less than 15.9%, which confirmed that the ic-ELISA performed well in various matrices.
Table 4. Recoveries, CVs, LODs, and linearity range of ABZs in spiked milk samples using ic-ELISA. (n = 3).

| ABZs in Milk Samples | Spiked Level (µg/L) | Recovery (%) | CV (%) | LOD (µg/L) | Linearity Range (µg/L) |
|----------------------|---------------------|-------------|--------|------------|------------------------|
| ABZ                  | 0.5                 | 87.5%       | 1.0%   | 0.05       | 0.08–0.4               |
|                      | 2                   | 82.1%       | 7.7%   |            |                        |
|                      | 10                  | 78.7%       | 6.9%   |            |                        |
| ABZSO₂               | 0.5                 | 94.2%       | 4.1%   | 0.05       | 0.08–0.5               |
|                      | 2                   | 71.4%       | 10.5%  |            |                        |
|                      | 10                  | 60.0%       | 6.8%   |            |                        |
| ABZSO                | 0.5                 | 105.1%      | 11.9%  | 0.05       | 0.1–2.5                |
|                      | 2                   | 98.7%       | 9.9%   |            |                        |
|                      | 10                  | 74.5%       | 7.9%   |            |                        |
| ABZNH₂SO₃            | 0.5                 | 108.0%      | 10.3%  | 0.50       | 1.5–73.5               |
|                      | 2                   | 76.6%       | 12.3%  |            |                        |
|                      | 10                  | 75.2%       | 2.9%   |            |                        |

Table 5. Recoveries, CVs, LODs, and linearity range of ABZNH₂SO₃ in spiked tissue samples using ic-ELISA. (n = 3).

| ABZNH₂SO₃ in Tissue Samples | Spiked Level (µg/kg) | Recovery (%) | CV (%) | LOD (µg/kg) | Linearity Range (µg/kg) |
|-----------------------------|----------------------|-------------|--------|-------------|-------------------------|
| Beef                        | 10                   | 84.1%       | 2.4%   | 1.12        | 2.3–25.9                |
|                             | 30                   | 91.6%       | 4.9%   |             |                        |
|                             | 90                   | 74.2%       | 6.6%   |             |                        |
| Liver                       | 10                   | 87.8%       | 4.5%   | 0.56        | 1.3–23.7                |
|                             | 30                   | 106.1%      | 9.1%   |             |                        |
|                             | 90                   | 108.8%      | 15.9%  |             |                        |

4. Conclusions

In this study, a new hapten was designed by exposing the characteristic sulfanyl group of ABZ as an epitope. Furthermore, one Mab 12F12 for simultaneously detection of ABZs including ABZNH₂SO₃ was prepared for the first time and with the highest affinity to date. The established ic-ELISA based on the Mab 12F12 presented times lower IC₅₀ values than previously reported and was suitable for the screening of ABZs in foodstuffs. The molecular recognition mechanism was briefly explained via computational chemistry analysis and indicated that the hydrophobicity of molecules and conformational factors might be the key factors that affect the binding between antibody and ABZs in this study, which might offer guides for antibody preparation to reduce the cost of trial-and-error in subsequent research.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/foods10123106/s1, Figure S1: 1 H NMR spectra of hapten.

Author Contributions: Conceptualization, S.S. and Z.W.; Methodology, S.S., L.D. and J.M.; software, S.S. and Y.B.; validation, W.Y.; formal analysis, W.Y.; investigation, X.Z.; resources, X.Z.; data curation, S.S.; writing—original draft preparation, S.S.; writing—review and editing, S.S., L.D., Y.B., J.M. and W.Y.; visualization, S.S. and X.Z.; supervision, Z.W., K.W. and S.Z.; project administration, Z.W.; funding acquisition, Z.W. and K.W. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Ministry of Science and Technology (MOST) for the National Key R&D Program of China, grant number 2018YFC1603500, Sanming Project of Medicine in Shenzhen (SZSM201611068), and supported by China Agriculture Research System of MOF and MARA.
Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Taylor, M.J.; Hoerauf, A.; Bockarie, M. Lymphatic filariasis and onchocerciasis. *Lancet* 2010, 376, 1175–1185. [CrossRef]
2. Gobbi, F.; Buonfrate, D.; Tamarozzi, F.; Degani, M.; Angheben, A.; Bisoffi, Z. Efficacy of high-dose albendazole with ivermectin for treating imported loiasis. *Italy. Emerg. Infect. Dis.* 2019, 25, 1574–1576. [CrossRef]
3. Macfarlane, C.L.; Budhathoki, S.S.; Johnson, S.; Richardson, M.; Garner, P. Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis. *Cochrane Db. Syst. Rev.* 2019, 1, CD003753. [CrossRef]
4. Budge, P.J.; Herbert, C.; Andersen, B.J.; Weil, G.J. Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature. *PLoS Negl. Trop. Dis.* 2018, 12, e0006454. [CrossRef]
5. Chami, G.F.; Bundy, D.A.P. More medicines alone cannot ensure the treatment of neglected tropical diseases. *Lancet Infect. Dis.* 2019, 19, 330–336. [CrossRef]
6. Pullan, R.L.; Halliday, K.E.; Oswald, W.E.; Mcharo, C.; Beaumont, E.; Kephia, S.; Witek-McManus, S.; Gichuki, P.M.; Allen, E.; Drake, T.; et al. Effects, equity, and cost of school-based and community-wide treatment strategies for soil-transmitted helminths in Kenya: A cluster-randomised controlled trial. *Lancet* 2019, 393, 2039–2050. [CrossRef]
7. Danaher, M.; De Ruyck, H.; Crooks, S.R.; Dowling, G.; O’Keeffe, M. Review of methodology for the determination of benzimidazole residues in biological matrices. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 2007, 845, 1–37. [CrossRef]
8. Schulz, J.D.; Neodo, A.; Coulibaly, J.T.; Keiser, J. Pharmacokinetics of albendazole, Albendazole sulfoxide, and albendazole sulfone determined from plasma, Blood, Dried-blood spots, And mitra samples of hookworm-infected adolescents. *Antimicrob. Agents Chemother.* 2019, 63, e02489-18. [CrossRef] [PubMed]
9. Thomsen, E.K.; Sanuku, N.; Baea, M.; Satofan, S.; Maki, E.; Lombore, B.; Schmidt, M.S.; Siba, P.M.; Weil, G.J.; Kazura, J.W.; et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. *Clin. Infect. Dis.* 2016, 62, 334–341. [CrossRef]
10. Ricken, F.J.; Nell, J.; Grüner, B.; Schmidberger, J.; Kaltenbach, T.; Kratzer, W.; Hillenbrand, A.; Henne-Brunns, D.; Deplazes, P.; Moller, P.; et al. Albendazole increases the inflammatory response and the amount of Em2-positive small particles of Echinococcus multilocularis (spems) in human hepatic alveolar echinococcosis lesions. *PLoS Negl. Trop. Dis.* 2017, 11, e0005636. [CrossRef] [PubMed]
11. The European Union. Commission Regulation (EU) No 37/2010 of 22 December 2009 on Pharmacologically Active Substances and Their Classification Regarding Maximum Residue Limits in Foodstuffs of Animal Origin; Official Journal of the European Union: Brussels, Belgium, 2010.
12. The, U.S. Food and Drug Administration. 21CFR556.34. Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs. Sec. 556.34 Albendazole. In *United States Pharmacopeia*. United States Pharmacopeia Convention: Rockville, MD, USA, 2021.
13. The Ministry of Agriculture and Rural Affairs of the People’s Republic of China. National Food Safety Standard-Maximum Residue Limits for Veterinary Drugs in Foods; GB 31650-2019; Standards Press of China: Beijing, China, 2019.
14. Li, S.; Liang, Q.; Ahmed, S.A.H. Simultaneous determination of five benzimidazoles in agricultural foods by core-shell magnetic covalent organic framework nanoparticle-based solid-phase extraction coupled with high-performance liquid chromatography. *Food Anal. Methods* 2020, 13, 1111–1118. [CrossRef] [PubMed]
15. Permura, A.D.; Tekko, I.A.; McCarthy, H.O.; Donnelly, R.F. New HPLC-MS method for rapid and simultaneous quantification of doxycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. *J. Pharm. Biomed. Anal.* 2019, 170, 243–253. [CrossRef]
16. Bach, T.; Bae, S.; D’Cunha, R.; Winokur, P.; An, G. Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxendazole in human plasma and its application to clinical pharmacokinetic study. *J. Pharm. Biomed. Anal.* 2019, 171, 111–117. [CrossRef]
17. Xu, N.; Dong, J.; Yang, Y.; Liu, Y.; Yang, Q.; Ai, X. Development of a liquid chromatography-tandem mass spectrometry method with modified QuEChERS extraction for the quantification of mebendazole and its metabolites, albendazole and its metabolites, and levamisole in edible tissues of aquatic animals. *Food Chem.* 2018, 269, 442–449. [CrossRef] [PubMed]
18. Tejada-Casado, C.; Moreno-Gonzalez, D.; Lara, F.J.; Garcia-Campana, A.M.; Del Olmo-Iruela, M. Determination of benzimidazoles in meat samples by capillary zone electrophoresis tandem mass spectrometry following dispersive liquid-liquid microextraction. *J. Chromatogr. A* 2017, 1490, 212–219. [CrossRef]
19. Xia, X.; Wang, Y.; Wang, X.; Li, Y.; Zhong, F.; Li, X.; Huang, Y.; Ding, S.; Shen, J. Validation of a method for simultaneous determination of nitroimidazoles, benzimidazoles and chloramphenicol in swine tissues by ultra-high-performance liquid chromatography-tandem mass spectrometry. *J. Chromatogr. A* 2013, 1292, 96–103. [CrossRef]
20. Guo, L.; Wu, X.; Liu, L.; Kuang, H.; Xu, C. Gold nanoparticle-based paper sensor for simultaneous detection of 11 benzimidazoles by one monoclonal antibody. *Small* 2018, 14, 1701782. [CrossRef] [PubMed]

21. Peng, D.; Jiang, N.; Wang, Y.; Chen, D.; Liu, Z.; Yuan, Z. Development and validation of an indirect competitive enzyme-linked immunosorbent assay for the detection of albendazole 2-aminosulfone residues in animal tissues. *Food Agric. Immunol.* 2015, 27, 273–287. [CrossRef]

22. Brandon, D.L.; Binder, R.G.; Bates, A.H.; Montague, W.C., Jr. Monoclonal antibody for multiresidue ELISA of benzimidazole anthelmintics in liver. *J. Agric. Food Chem.* 1994, 42, 1588–1594. [CrossRef]

23. Brandon, D.L.; Holland, K.P.; Dreas, J.S.; Henry, A.C. Rapid screening for benzimidazole residues in bovine liver. *J. Agric. Food Chem.* 1998, 46, 3653–3656. [CrossRef]

24. Köhler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 1975, 256, 495–497. [CrossRef] [PubMed]

28. Lu, T.; Chen, F. Multiwfn, A multifunctional wavefunction analyzer. *J Comput. Chem.* 2012, 33, 580–592. [CrossRef]

29. Lu, T.; Chen, F. Quantitative analysis of molecular surface based on improved marching tetrahedra algorithm. *J. Mol. Graph. Model.* 2012, 38, 314–323. [CrossRef]

31. Xu, Z.L.; Shen, Y.D.; Beier, R.C.; Yang, J.Y.; Lei, H.; Wang, H.; Sun, Y.M. Application of computer-assisted molecular modeling for immunoassay of low molecular weight food contaminants: A review. *Anal. Chim. Acta.* 2009, 647, 125–136. [CrossRef] [PubMed]

34. Newman, D.J.; Price, C.P. Molecular aspects of design of immunoassays for drugs. *Ther. Drug Monit.* 1996, 18, 493–497. [CrossRef] [PubMed]

35. Wang, Z.; Luo, P.; Cheng, L.; Zhang, S.; Shen, J. Hapten-antibody recognition studies in competitive immunoassay of α-zearalanol analogs by computational chemistry and pearson correlation analysis. *J. Mol. Recognit.* 2011, 24, 815–823. [CrossRef] [PubMed]